24  Pickerson P,Steurer W,Steiger J,et al.Cytokines and the Th1/Th2 paradigm in transplantation.Curr Opin Immunol,1994,6:757-764.

　　25  Yamada J,Yoshida M,Taylor AW,et al.Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in high risk eyes.J Immunol,1999,162:5247-5255.

　　26  Qin S,Cobbold SP,Pope H,et al.‘Infectious’ transplantation tolerance.Science,1993,259:974-976.

　　27  Kato H,Ritter T,Ke B,et al.Adenovirus,mediated gene transfer of IL-4 prolongs rat rnal allograft suevival and inhibits the p21(ras) activation pathway.Transplant Proc,2000,32:245-246.

　　28  Sonoda K H,M Exley,S Snapper,et al. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site.J Exp Med,1999,190:1215.

　　29  Gumperz JE.Murine CD1d-restricted T cell recognition of cellular lipids.Immunity,2000,12:211-221.

　　30  Lodfrey D L,K J Hammond,L D Poulton,et al. NKT cells:facts,functions and fallacies.Immunol,2000,21:573.

　　31  Singh N.Cutting edge:activation of NKT cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.J Immunol,1999,163:2373-2377.

　　32  Sonoda K H,M Taniguchi,J Stein-Streilein.Long-Term Survival of Corneal Allografts Is Dependent on Intact CD1d-Reactive NKT Cells.J Immunol,2002,168:2028-2034.

　　33  Smiley S T,M H Kaplan,M J Grusby.Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells.Science,1997,275:977.

　　34  Sonoda K H,M Exley,S Snapper,et al. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site.J Exp Med,1999,1190:1215.

　　35  Thompson P,Xu D,Brunette I,et al.Combined effect of rapamycin and 9cyclosporine in the prevention of rat corneal allograft rejection.Transplantation Proc,1998,30(4):1033-1035.

　　36  Reihard T,Reis A,Bohring D,et al.Systemic mycophenolate mofetil in comparison with systemic cyclosporine A in high-risk keratoplasty patients:3 years results of a randomized prospective clinical trial.Graefes Arch Clin Exp Ophthalmol,2001,239(5):367-372.

　　37  Fink N,Stark WJ,Maguire MG,et al.Effectiveness of histocompatibility matching in high-risk corneal transplantation:asummary of results from the collaborative Corneal Transplantation Studies.Cesk Oftalmol,1994,50:3-12.

　　38  Annette Busch,Wayne A Marasco,Cornelia Doebis,et al.MHC class Ⅰ manipulation on cell surfaces by gene transfer of anti-MHC class Ⅰ intrabodies-a tool for decreased immunogenicity of allogeneic tissue and cell transplants.Method,2004,34:240-249.

　　39  Backman-Petersson E,Butcher GW,Hedlund G.Self-MHC class Ⅰa (RT1-A(n)) protects cells co-expressing the activatory allogeneic MHC class Ⅰb molecule (RT1-E(u)) from NK lysis.Int Immunol,2000,12:843-850.

　　40  Ming-Ling Tsai,Show-Li Chen,Ping-I Chou,et al.Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium,2002,43:751-757.

　　41  Sato Y,Ajiki T,Inoue S.Gene silencing in rat-liver and limb grafts by rapid injection of small interference RNA.Trasplantation,2005,27(79):240-243.

　　42  Connolly ML.Sovent-accessible surfaces of proteins and nucleic acid.Science,1983,221:709-713.

　　43  Song Li,Jimin Gao,Takashi Saton,et al.Acomputer screening approach to immunoglobulin superfamily structures and interactions:Discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics.Proc Natl Acad Sci USA,1997,94(1):73-78.

上一页  [1] [2] [3] [4] [5] [6] [7]